- This event has passed.
Meet the Johnson & Johnson Innovation Team
March 22, 2016 @ 10:30 am - 12:30 pm
Johnson & Johnson Innovation recently announced the opening of JLABS @ Toronto, a partnership with University of Toronto, the Ontario Government and the MaRS Discovery District. You have another chance to learn more on the progress of this ground-breaking project. Join us and hear from Johnson & Johnson Innovation in person.
How can Johnson & Johnson Innovation help you reach your goals? Johnson & Johnson Innovation (JJI) is supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS (JLABS), with the ultimate aim of enabling commercialization of new healthcare solutions for patients. We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The JJI team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
On March 22, hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:30am | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on February 16th.
Johnson & Johnson Innovation Participating Representatives:
Kuldeep Neote | Senior Director, New Ventures, J&J Innovation read bio»
Marian Nakada | Vice President, Venture Investments, J&J Innovation read bio»
Jennifer Hamilton | Senior Director, New Ventures – Canada, J&J Innovation read bio»
Ibraheem Badejo | Senior Director, New Ventures, J&J Innovation read bio»
FREE | General Public
FREE | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on March 21st (or sold out).
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on February 16th. Your application will be reviewed and you will be notified of acceptance on February 29th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with… Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA’s Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Johnson & Johnson Innovation Participating Representatives’ Biographies:
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.
Marian Nakada, Ph.D., Vice President, Venture Investments, Johnson & Johnson Innovation, Boston
Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston. She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics. Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy. Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor’s technologies were competitive with the industry. Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Jennifer Hamilton, Ph.D. | Senior Director, New Ventures – Canada, Johnson & Johnson Innovation
Jennifer Hamilton is the innovation scout in Canada for the Johnson & Johnson Innovation. Based in Vancouver, British Columbia, she is responsible for identifying emerging healthcare technologies and business opportunities involving pharmaceutical, device, biomaterial, health IT and consumer innovations in Canada. Prior to joining J&J in 2010 she spent 17 years in venture capital as Venture Partner at UK-based Nomura Phase4 Ventures and as Investment Director with Rothschild Asset Management which managed two global publicly traded funds. Jennifer has a Ph.D. (Experimental Pathology/Lipid Metabolism) from the University of British Columbia.
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.